Skip to content
#gene editing Case report Open access

Liver biopsy confirms precise and efficient correction of SERPINA1 after in vivo Base Editing in a Patient with Alpha-1 Antitrypsin Deficiency.

Nov 2026 · Journal of Hepatology · 0 citations · 11 references
Medicine

TL;DR

Sustained biologically active AAT levels support feasibility and potential of this approach for the treatment of AATD, and substantial and precise hepatic correction of the pathogenic SERPINA1 PI*ZZ variant is achieved.

Abstract

Background

Alpha-1 antitrypsin deficiency (AATD) caused by the PI*ZZ genotype (Glu342Lys) is characterized by hepatic accumulation of misfolded AAT-Z protein and reduced circulating AAT levels, leading to progressive liver disease and pulmonary emphysema. Gene correction therapy represents a potentially curative approach by directly correcting the underlying genetic defect. We report the first clinical case with direct assessment of hepatic gene correction by liver biopsy following in vivo base editing in a patient with AATD. METHODS/CASE PRESENTATION We report the case of a 66-year-old male patient with PI*ZZ AATD who underwent gene correction therapy within the YOLT-202 phase I/Ia clinical trial (clinical trial.gov ID NCT07193615). Ten weeks after treatment a liver biopsy was performed to assess hepatic histology in the context of pre-existing F2 fibrosis identified by elastography before treatment. Liver tissue was analyzed for correction of the Pi*ZZ variant using Sanger and Illumina sequencing, including assessment of bystander and off-target editing. Serum levels and biological activity of AAT were assessed longitudinally using an elastase inhibition assay.

Results

Liver biopsy showed no evidence of hepatic inflammation and demonstrated correction of the PI*ZZ variant in 54% of alleles by Sanger and 57% by Illumina sequencing without detectable off-target signals. Following a transient post-treatment increase in transaminases, liver enzymes returned to baseline. Monthly measurements demonstrated sustained circulating AAT levels with preserved biological activity, as assessed by elastase inhibition, throughout follow-up.

Conclusions

In vivo base editing achieved substantial and precise hepatic correction of the pathogenic SERPINA1 PI*ZZ variant, without concerning histological findings or detectable bystander or off-target editing. Sustained biologically active AAT levels support feasibility and potential of this approach for the treatment of AATD.

Read PDF

Similar papers

#gene editing Review Open access Oct 2026

Pushing the Boundaries of Knowledge in Alpha-1 Antitrypsin Deficiency.

Cutting-edge preclinical and translational developments with potential to redefine AATD management and move toward curative approaches are highlighted, highlighting cutting-edge preclinical and translational developments with potential to redefine AATD management.

J. M. Hernández-Pérez, S. Castillo-Corullón, I. Ferrarotti et al. · 0 citations
Review Open access Sep 2026

Liver Disease in Transaldolase Deficiency: Molecular Basis, Genotype–Phenotype Relationships, and Transplantation Outcomes—A Systematic Review

Transaldolase deficiency (TALDO-D) is an ultra-rare disorder of the non-oxidative pentose phosphate pathway with prominent liver disease and systemic accumulation of polyols and seven-carbon sugars. We systematically reviewed hepatic manifestations, molecular findings, genotype–phenotype relationships, and liver transp...

Patryk Lipiński, Piotr Socha, I. Jankowska et al. · 0 citations
Case report Open access Sep 2026

PKHD1 biallelic defects caused Severe Hepatic Fibrosis and polycystic kidney: Identification of a novel pathogenic variant in a Chinese family.

Background Autosomal recessive polycystic kidney disease (ARPKD) is a rare hereditary ciliopathy, clinically characterized by fibrocystic changes in the kidneys and liver. The disease is manifested by hepatic fibrosis and significantly enlarged, echogenic kidneys with fusiform dilation of the collecting ducts. ARPKD is...

G. Zheng, H. Feryel, J. Si et al. · 0 citations
Oct 2026

In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease driven by continuous hepatic production of misfolded transthyretin. Existing therapies slow progression but require chronic administration. YOLT-201 is an in vivo CRISPR-Cas9 gene-editing therapy delivered by lipid nanopa...

X. Guo, H. Yan, J. Liao et al. · 0 citations
Open access Oct 2026

Challenges in targeted therapy for cystic fibrosis in a patient with the complex allele [L467F; F508del]: from failure of first-line modulator therapy to successful use of vanzacaftor+tezacaftor+deutivacaftor combination

Cystic fibrosis (CF) is the most common inherited autosomal recessive disorder, caused by mutations in the CFTR gene. The introduction of CFTR modulators has fundamentally changed the prognosis and quality of life of patients. However, the presence of complex alleles may significantly affect the efficacy of targeted th...

А. V. Nistarova, S. I. Petrova, Y. V. Peshekhonova et al. · 0 citations

Related blog posts

Microsoft Research Blog Nov 12, 2026

Microsoft Research Focus – Edition #98

What's new in research at Microsoft? Host Anson Ho explores the latest, including AI-powered universal translation, a breakthrough in a 31-year-old mathematics challenge, and advances making AI coding agents faster and more efficient.  The post Microsoft Research Focus – Edition #98 appeared first on Microsoft Research.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.